TY - JOUR AU - Saijo, N. PY - 2010 DA - 2010// TI - Targeted therapies: tyrosine-kinase inhibitors–new standard for NSCLC therapy JO - Nat Rev Clin Oncol VL - 7 UR - https://doi.org/10.1038/nrclinonc.2010.168 DO - 10.1038/nrclinonc.2010.168 ID - Saijo2010 ER - TY - STD TI - NCCN Clinical Practice Guidelines in Oncology Non-Small Cell Lung Cancer Version 6.2020. https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. 24 June 2020. UR - https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf ID - ref2 ER - TY - JOUR AU - Xu, Q. AU - Zhou, F. AU - Liu, H. AU - Jiang, T. AU - Li, X. AU - Xu, Y. PY - 2018 DA - 2018// TI - Consolidative local ablative therapy improves the survival of patients with synchronous oligometastatic NSCLC harboring EGFR activating mutation treated with first-line EGFR-TKIs JO - J Thorac Oncol VL - 13 UR - https://doi.org/10.1016/j.jtho.2018.05.019 DO - 10.1016/j.jtho.2018.05.019 ID - Xu2018 ER - TY - JOUR AU - Hu, F. AU - Xu, J. AU - Zhang, B. AU - Li, C. AU - Nie, W. AU - Gu, P. PY - 2019 DA - 2019// TI - Efficacy of local consolidative therapy for oligometastatic lung adenocarcinoma patients harboring epidermal growth factor receptor mutations JO - Clin Lung Cancer VL - 20 UR - https://doi.org/10.1016/j.cllc.2018.09.010 DO - 10.1016/j.cllc.2018.09.010 ID - Hu2019 ER - TY - JOUR AU - Tang, Y. AU - Xia, B. AU - Xie, R. AU - Xu, X. AU - Zhang, M. AU - Wu, K. PY - 2020 DA - 2020// TI - Timing in combination with radiotherapy and patterns of disease progression in non-small cell lung cancer treated with EGFR-TKI JO - Lung Cancer (Amsterdam, Netherlands) VL - 140 UR - https://doi.org/10.1016/j.lungcan.2019.12.009 DO - 10.1016/j.lungcan.2019.12.009 ID - Tang2020 ER - TY - JOUR AU - Zheng, L. AU - Wang, Y. AU - Xu, Z. AU - Yang, Q. AU - Zhu, G. AU - Liao, X. Y. PY - 2019 DA - 2019// TI - Concurrent EGFR-TKI and thoracic radiotherapy as first-line treatment for stage IV non-small cell lung cancer harboring EGFR active mutations JO - Oncologist VL - 24 UR - https://doi.org/10.1634/theoncologist.2019-0285 DO - 10.1634/theoncologist.2019-0285 ID - Zheng2019 ER - TY - JOUR AU - Yen, Y. C. AU - Hsu, H. L. AU - Chang, J. H. AU - Lin, W. C. AU - Chang, Y. C. AU - Chang, C. L. PY - 2018 DA - 2018// TI - Efficacy of thoracic radiotherapy in patients with stage IIIB-IV epidermal growth factor receptor-mutant lung adenocarcinomas who received and responded to tyrosine kinase inhibitor treatment JO - Radiother Oncol J Eur Soc Ther Radiol Oncol VL - 129 UR - https://doi.org/10.1016/j.radonc.2018.03.007 DO - 10.1016/j.radonc.2018.03.007 ID - Yen2018 ER - TY - JOUR AU - Zhuang, H. AU - Yuan, Z. AU - Chang, J. Y. AU - Wang, J. AU - Pang, Q. AU - Zhao, L. PY - 2014 DA - 2014// TI - Radiation pneumonitis in patients with non–small-cell lung cancer treated with erlotinib concurrent with thoracic radiotherapy JO - J Thorac Oncol VL - 9 UR - https://doi.org/10.1097/JTO.0000000000000126 DO - 10.1097/JTO.0000000000000126 ID - Zhuang2014 ER - TY - JOUR AU - Jia, W. AU - Guo, H. AU - Jing, W. AU - Jing, X. AU - Li, J. AU - Wang, M. PY - 2020 DA - 2020// TI - An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib JO - Radiother Oncol J Eur Soc Therap Radiol Oncol VL - 152 UR - https://doi.org/10.1016/j.radonc.2020.07.051 DO - 10.1016/j.radonc.2020.07.051 ID - Jia2020 ER - TY - STD TI - National Institute of Cancer. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50. UR - https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50 ID - ref10 ER - TY - JOUR AU - Wan, J. AU - Cohen, V. AU - Agulnik, J. AU - Faria, S. AU - Portelance, L. AU - Ofiara, L. PY - 2009 DA - 2009// TI - Unexpected high lung toxicity from radiation pneumonitis in a phase I/II trial of concurrent erlotinib with limited field radiation for intermediate prognosis patients with stage III or inoperable stage IIB non-small-cell lung cancer (NSCLC) JO - Int J Radiat Oncol Biol Phys VL - 75 UR - https://doi.org/10.1016/j.ijrobp.2009.07.267 DO - 10.1016/j.ijrobp.2009.07.267 ID - Wan2009 ER - TY - JOUR AU - Okamoto, I. AU - Takahashi, T. AU - Okamoto, H. AU - Nakagawa, K. AU - Watanabe, K. AU - Nakamatsu, K. PY - 2011 DA - 2011// TI - Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor JO - Lung Cancer (Amsterdam, Netherlands) VL - 72 UR - https://doi.org/10.1016/j.lungcan.2010.08.016 DO - 10.1016/j.lungcan.2010.08.016 ID - Okamoto2011 ER - TY - JOUR AU - Rodrigues, G. AU - Lock, M. AU - D'Souza, D. AU - Yu, E. AU - Dyk, J. PY - 2004 DA - 2004// TI - Prediction of radiation pneumonitis by dose—volume histogram parameters in lung cancer—a systematic review JO - Radiother Oncol J Eur Soc Ther Radiol Oncol VL - 71 UR - https://doi.org/10.1016/j.radonc.2004.02.015 DO - 10.1016/j.radonc.2004.02.015 ID - Rodrigues2004 ER - TY - JOUR AU - Chang, C. C. AU - Chi, K. H. AU - Kao, S. J. AU - Hsu, P. S. AU - Tsang, Y. W. AU - Chang, H. J. PY - 2011 DA - 2011// TI - Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience JO - Lung Cancer (Amsterdam, Netherlands) VL - 73 UR - https://doi.org/10.1016/j.lungcan.2010.12.007 DO - 10.1016/j.lungcan.2010.12.007 ID - Chang2011 ER - TY - JOUR AU - Suzuki, H. AU - Aoshiba, K. AU - Yokohori, N. AU - Nagai, A. PY - 2003 DA - 2003// TI - Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis JO - Can Res VL - 63 ID - Suzuki2003 ER - TY - JOUR AU - Chinnaiyan, P. AU - Huang, S. AU - Vallabhaneni, G. AU - Armstrong, E. AU - Varambally, S. AU - Tomlins, S. A. PY - 2005 DA - 2005// TI - Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva) JO - Can Res VL - 65 UR - https://doi.org/10.1158/0008-5472.CAN-04-3547 DO - 10.1158/0008-5472.CAN-04-3547 ID - Chinnaiyan2005 ER - TY - JOUR AU - Harada, C. AU - Kawaguchi, T. AU - Ogata-Suetsugu, S. AU - Yamada, M. AU - Hamada, N. AU - Maeyama, T. PY - 2011 DA - 2011// TI - EGFR tyrosine kinase inhibition worsens acute lung injury in mice with repairing airway epithelium JO - Am J Respir Crit Care Med VL - 183 UR - https://doi.org/10.1164/rccm.201002-0188OC DO - 10.1164/rccm.201002-0188OC ID - Harada2011 ER - TY - JOUR AU - Miyake, K. AU - Tani, K. AU - Kakiuchi, S. AU - Suzuka, C. AU - Toyoda, Y. AU - Kishi, J. PY - 2012 DA - 2012// TI - Epidermal growth factor receptor-tyrosine kinase inhibitor (gefitinib) augments pneumonitis, but attenuates lung fibrosis in response to radiation injury in rats JO - J Med Investig JMI VL - 59 UR - https://doi.org/10.2152/jmi.59.174 DO - 10.2152/jmi.59.174 ID - Miyake2012 ER - TY - JOUR AU - Zhuang, H. AU - Hou, H. AU - Yuan, Z. AU - Wang, J. AU - Pang, Q. AU - Zhao, L. PY - 2014 DA - 2014// TI - Preliminary analysis of the risk factors for radiation pneumonitis in patients with non-small-cell lung cancer treated with concurrent erlotinib and thoracic radiotherapy JO - OncoTargets Ther VL - 7 UR - https://doi.org/10.2147/OTT.S62707 DO - 10.2147/OTT.S62707 ID - Zhuang2014 ER - TY - JOUR AU - Shi, Y. AU - Zhang, L. AU - Liu, X. AU - Zhou, C. AU - Zhang, L. AU - Zhang, S. PY - 2013 DA - 2013// TI - Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial JO - Lancet Oncol VL - 14 UR - https://doi.org/10.1016/S1470-2045(13)70355-3 DO - 10.1016/S1470-2045(13)70355-3 ID - Shi2013 ER - TY - JOUR AU - Zhao, Y. AU - Liu, J. AU - Cai, X. AU - Pan, Z. AU - Liu, J. AU - Yin, W. PY - 2019 DA - 2019// TI - Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis JO - BMJ VL - 367 UR - https://doi.org/10.1136/bmj.l5460 DO - 10.1136/bmj.l5460 ID - Zhao2019 ER - TY - JOUR AU - Tan, F. AU - Shen, X. AU - Wang, D. AU - Xie, G. AU - Zhang, X. AU - Ding, L. PY - 2012 DA - 2012// TI - Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies JO - Lung Cancer (Amsterdam, Netherlands) VL - 76 UR - https://doi.org/10.1016/j.lungcan.2011.10.023 DO - 10.1016/j.lungcan.2011.10.023 ID - Tan2012 ER - TY - JOUR AU - Liu, D. AU - Jiang, J. AU - Zhang, L. AU - Tan, F. AU - Wang, Y. AU - Hu, P. PY - 2011 DA - 2011// TI - Metabolite characterization of a novel anti-cancer agent, icotinib, in humans through liquid chromatography/quadrupole time-of-flight tandem mass spectrometry JO - Rapid Commun Mass Spectrom VL - 25 UR - https://doi.org/10.1002/rcm.5061 DO - 10.1002/rcm.5061 ID - Liu2011 ER - TY - JOUR AU - Zhao, Q. AU - Shentu, J. AU - Xu, N. AU - Zhou, J. AU - Yang, G. AU - Yao, Y. PY - 2011 DA - 2011// TI - Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors JO - Lung Cancer (Amsterdam, Netherlands) VL - 73 UR - https://doi.org/10.1016/j.lungcan.2010.11.007 DO - 10.1016/j.lungcan.2010.11.007 ID - Zhao2011 ER - TY - JOUR AU - Ranson, M. AU - Hammond, L. A. AU - Ferry, D. AU - Kris, M. AU - Tullo, A. AU - Murray, P. I. PY - 2002 DA - 2002// TI - ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial JO - J Clin Oncol VL - 20 UR - https://doi.org/10.1200/JCO.2002.10.112 DO - 10.1200/JCO.2002.10.112 ID - Ranson2002 ER - TY - JOUR AU - Tsujino, K. AU - Hirota, S. AU - Endo, M. AU - Obayashi, K. AU - Kotani, Y. AU - Satouchi, M. PY - 2003 DA - 2003// TI - Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer JO - Int J Radiat Oncol Biol Phys VL - 55 UR - https://doi.org/10.1016/S0360-3016(02)03807-5 DO - 10.1016/S0360-3016(02)03807-5 ID - Tsujino2003 ER - TY - JOUR AU - Oh, D. AU - Ahn, Y. C. AU - Park, H. C. AU - Lim, D. H. AU - Han, Y. PY - 2009 DA - 2009// TI - Prediction of radiation pneumonitis following high-dose thoracic radiation therapy by 3 Gy/fraction for non-small cell lung cancer: analysis of clinical and dosimetric factors JO - Jpn J Clin Oncol VL - 39 UR - https://doi.org/10.1093/jjco/hyn158 DO - 10.1093/jjco/hyn158 ID - Oh2009 ER -